To identify therapeutic drugs to selectively kill high-STMN1-expressing HCC cells, we mined the CTRP database and found that HCC cells with high STMN1 mRNA expression were sensitive to MST-312 (a telomerase inhibitor) and GMX-1778 (a competitive inhibitor of nicotinamide phosphoribosyltransferase) but resistant to BRD-K34099515 (unknown function) and Tacrolimus/FK506 (an immunosuppressive drug) (Figure 4A). This evidence concerns the gene STMN1 and hepatocellular carcinoma.